Parishin degrades CXCL2 via ubiquitination to limit myeloid-derived suppressor cells and potentiate antitumor immunity after incomplete radiofrequency ablation in hepatocellular carcinoma.
Radiofrequency ablation (RFA) is a standard curative therapy for early-stage hepatocellular carcinoma (HCC). However, some patients experience incomplete RFA (iRFA), and the chemokines and cytokines released subsequent to iRFA can promote tumor progression. Based on transcriptomic data from HCC patient-derived organoid...